adenine has been researched along with Abnormalities, Congenital in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 8.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
| "During follow-up, no bone fractures were reported to have occurred; 12/368 creatinines and seven out of 305 phosphates were grade one (16) or two (three) in 14 children with no effect of in utero tenofovir (p>0." | 6.77 | Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. ( Chidziva, E; Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kizito, H; Kyomugisha, H; Munderi, P; Musoke, P; Nalumenya, R; Nathoo, K; Russell, EC; Spyer, M; Tumukunde, D; Walker, AS; Zalwango, E, 2012) |
| " Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 4.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
| "During follow-up, no bone fractures were reported to have occurred; 12/368 creatinines and seven out of 305 phosphates were grade one (16) or two (three) in 14 children with no effect of in utero tenofovir (p>0." | 2.77 | Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. ( Chidziva, E; Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kizito, H; Kyomugisha, H; Munderi, P; Musoke, P; Nalumenya, R; Nathoo, K; Russell, EC; Spyer, M; Tumukunde, D; Walker, AS; Zalwango, E, 2012) |
| "Primary outcomes were major birth defects rates with exposure to all antivirals, individual classes, and drugs compared to population-based controls." | 1.38 | Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. ( Aguilar, C; Brown, RS; Buti, M; Fagan, EA; Leu, CS; Pereira, MR; Tilson, HH; Verna, EC, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foster, C | 1 |
| Lyall, H | 1 |
| Olmscheid, B | 1 |
| Pearce, G | 1 |
| Zhang, S | 1 |
| Gibb, DM | 2 |
| Kang, IN | 1 |
| Musa, M | 1 |
| Harun, F | 1 |
| Junit, SM | 1 |
| Schleenvoigt, BT | 1 |
| Stallmach, A | 1 |
| Pletz, MW | 1 |
| Kizito, H | 1 |
| Russell, EC | 1 |
| Chidziva, E | 1 |
| Zalwango, E | 1 |
| Nalumenya, R | 1 |
| Spyer, M | 1 |
| Tumukunde, D | 1 |
| Nathoo, K | 1 |
| Munderi, P | 1 |
| Kyomugisha, H | 1 |
| Hakim, J | 1 |
| Grosskurth, H | 1 |
| Gilks, CF | 1 |
| Walker, AS | 1 |
| Musoke, P | 1 |
| Brown, RS | 1 |
| Verna, EC | 1 |
| Pereira, MR | 1 |
| Tilson, HH | 1 |
| Aguilar, C | 1 |
| Leu, CS | 1 |
| Buti, M | 1 |
| Fagan, EA | 1 |
| Viana, M | 1 |
| Aruoma, OI | 1 |
| Herrera, E | 1 |
| Bonet, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)[NCT01066858] | 1,765 participants (Actual) | Observational | 2011-03-22 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for adenine and Abnormalities, Congenital
| Article | Year |
|---|---|
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2009 |
1 trial available for adenine and Abnormalities, Congenital
| Article | Year |
|---|---|
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Topics: Abortion, Spontaneous; Adenine; Adult; Anti-HIV Agents; Body Height; Body Weight; Breast Feeding; Bu | 2012 |
4 other studies available for adenine and Abnormalities, Congenital
| Article | Year |
|---|---|
Characterization of mutations in the FOXE1 gene in a cohort of unrelated Malaysian patients with congenital hypothyroidism and thyroid dysgenesis.
Topics: Adenine; Amino Acid Sequence; Animals; Cohort Studies; Congenital Abnormalities; DNA Primers; Forkhe | 2010 |
Tenofovir induced acute kidney injury in a patient with unilateral renal agenesis despite initially non-impaired renal function.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Congenital Abnormalities; HIV Infections; Huma | 2011 |
Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry.
Topics: Adenine; Adult; Antiviral Agents; Congenital Abnormalities; Female; Hepatitis B; Hepatitis B virus; | 2012 |
Oxidative damage in pregnant diabetic rats and their embryos.
Topics: Adenine; Animals; Congenital Abnormalities; Cytosine; Diabetes Mellitus, Experimental; DNA Adducts; | 2000 |